System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Vlad Ratziu is an expert in Hepatology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Vlad Ratziu in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Liver Cirrhosis. Vlad Ratziu has authored 744 publications, the most recent in 2026, and is an investigator in 55 clinical trials, 10 of them ongoing. SLR score: 4,010 (community average: 125). How the SLR is computed.

LeadR Profile

Vlad Ratziu Pitié-Salpêtrière Hospital France
4 010 ScienceLeadR Reputation 4010

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1992 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 744

Citations

Citations: 72 903 1st author: 98 Last author: 109 Unique author: 22

Main journals

J Hepatol 298
Hepatology 54
Gastroenterology 27
Aliment Pharmacol Ther 23
Gastroenterol Clin Biol 16

Best Journals

J Hepatol 77
N Engl J Med 13
Nat Med 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
PMID 42617506 — liver diseases, multiple chronic conditions, liver		JHEP Rep20263
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.
PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors		Liver Int20260
From the Editor's Desk..
PMID 42618137 — liver diseases, liver		J Hepatol Top journal20260
Metabolic Dysfunction-associated Steatotic Liver Disease in Romania: A Multidisciplinary Position Paper on Prevalence, Clinical Spectrum, Prevention, Screening and Management.
PMID 42617101 — liver diseases, fibrosis, non-alcoholic fatty liver disease, phenotype, liver, prevalence		J Gastrointestin Liver Dis20260
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
PMID 42545725 — liver diseases, fibrosis, non-alcoholic fatty liver disease, liver, body weight, weight loss, therapeutics, mediation analysis, negotiating		Hepatology20261

Clinical Studies 55

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8 Study Chair: 1

By phase:

Phase 2 26
Phase 3 16
N/A 13

By status:

Completed 32
Recruiting 10
Active not recruiting 6
Terminated 4
Unknown 2
Not yet recruiting 1

By type:

Interventional 47
Observational 8

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 3
multicentric5to9 1
multicentricup10 42

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH)
2024-512895-36-00 — safety, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic		Phase 3Recruiting2025
Development of a New Method for Liver Stiffness Measurement Using FibroScan
NCT06519331 — liver diseases, research design, elasticity imaging techniques, liver, research, fibroscan, liver stiffness		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS